JAK inhibitors

Lilly

Biotech

Lilly’s $2.3B Ajax drug works ‘right out of the gate’

The early data showed the novel JAK2 inhibitor “started working right out of the gate, with a good safety profile,” Lilly’s Jake Van Naarden said.

Angus Liu Jun 13, 2026 11:15am

photo of a pair of hands that show the skin condition vitiligo

Incyte’s vitiligo bet scores ph. 3 wins but can’t shake off Rinvoq

Apr 28, 2026 9:52am

Eli Lilly booth at AACR 2026

Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax

Apr 27, 2026 8:25am

Sanofi

Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am

Close up shot of the target from a dart game

Lynk sees ph. 3 eczema win as proof of JAK inhibitor's potential

Mar 2, 2026 8:55am

business targets illustration

Lynk targets the JAK pot with phase 3 rheumatoid arthritis win

Jan 12, 2026 8:45am